Predictors of Cardiovascular Disease in Individuals With Dysbetalipoproteinemia: A Prospective Study in the UK Biobank
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae618 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Martine Paquette und 4 weiteren Autor:innen. Beteiligte Einrichtung: Lipids, Nutrition, and Cardiovascular Prevention Clinic of the Montreal Clinical Research Institute, Montreal, QC H2W 1R7, Canada. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Hyperlipoproteinemia Type III, Atherosclerosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Background
Dysbetalipoproteinemia (DBL) is a disorder of remnant cholesterol metabolism associated with a severe risk of atherosclerotic cardiovascular disease (ASCVD).
Objective
The objective of this study was to investigate the univariate and multivariate predictors of ASCVD in individuals with DBL.
Methods
Data from 2699 individuals with ɛ2/ɛ2 genotypes from the UK Biobank were included in this study. DBL was defined as having an ɛ2ɛ2 genotype with evidence of dyslipidemia, defined as total cholesterol ≥ 200 mg/dL (5.2 mmol/L) and triglyceride ≥ 175 mg/dL (2.0 mmol/L) or lipid-lowering therapy use (n = 964).
Results
Age, hypertension, waist circumference, and a polygenic risk score for coronary artery disease (PRSCAD) were independent predictors of ASCVD among individuals with DBL. Cumulative ASCVD-free survival was lower in the ɛ2/ɛ2 DBL group (84%) compared to the ɛ2/ɛ2 non-DBL group (94%) (P < .0001) and for DBL individuals with a PRSCAD ≥ median (79%) compared to those with a PRSCAD < median (89%) (P = .001).
Conclusion
We show in a large prospective cohort that a PRSCAD predicts the ASCVD risk among individuals with DBL. The findings of the present study highlight the need for better risk stratification in ɛ2/ɛ2 carriers to identify high-risk individuals who would need aggressive cardiovascular management despite their low apolipoprotein B value.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Lipids, Nutrition, and Cardiovascular Prevention Clinic of the Montreal Clinical Research Institute, Montreal, QC H2W 1R7, Canada.
- Centre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, BC V6Z 1Y6, Canada.
- Department of Medicine, University of British Columbia, Vancouver, BC V6Z 1Y6, Canada.
- Department of Medicine, Division of Endocrinology, Université de Montréal, Montréal, QC H3T 1J4, Canada.
- Department of Medicine, Divisions of Experimental Medicine and Medical Biochemistry, McGill University, Montreal, QC H3G 2M1, Canada.
ORCID-Profile: Martine Paquette, Mark Trinder, Simon-Pierre Guay, Liam R Brunham, Alexis Baass
Zitieren
APA
Paquette, M., Trinder, M., Guay, S. P., Brunham, L. R., & Baass, A. (2025). Predictors of Cardiovascular Disease in Individuals With Dysbetalipoproteinemia: A Prospective Study in the UK Biobank. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae618
Vancouver
Paquette M, Trinder M, Guay SP, Brunham LR, Baass A. Predictors of Cardiovascular Disease in Individuals With Dysbetalipoproteinemia: A Prospective Study in the UK Biobank. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae618
BibTeX
@article{Paquette2025,
author = {Paquette, Martine and Trinder, Mark and Guay, Simon-Pierre and Brunham, Liam R and Baass, Alexis},
title = {Predictors of Cardiovascular Disease in Individuals With Dysbetalipoproteinemia: A Prospective Study in the UK Biobank},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae618}
}
EUVIMED